Safety questions that still need answers
TB-500 safety needs tests of the substance you'd receive
Do the existing tests settle your risks? They don't. Human safety evidence is missing for the shorter substance. The answers explain which concerns remain open.
Repair and tumor growth can both need new blood vessels
Why does a repair claim raise safety questions? New blood vessels bring blood to injured areas. A tumor could get blood from those vessels too.
Your possible risk hasn't been settled for TB-500.
The closest human safety study gave thymosin beta-4 through a vein [6]. That larger protein differs from the shorter substance you're considering. You need tests of the treatment you're considering.
Your TB-500 side-effect questions remain open despite that other study.
TB-500 side effects need their own human safety study
Your risks with TB-500 haven't been checked in human treatment comparisons. Thymosin beta-4 was tested up to 1260 milligrams. That early safety study, called Phase 1, reported no serious harm [6].
The supplied findings don't name the mild or moderate problems.
You can't identify specific symptoms from those findings. The study also doesn't settle the shorter substance's possible tumor risk.
TB-500 has an unresolved concern about supporting tumor growth
Researchers have found high thymosin beta-4 levels in several cancers. Research connects that protein with cancer spreading and gaining blood vessels [5]. More blood could help a tumor grow.
That's a possible safety concern for you.
Human tests haven't proved TB-500 causes that harm. Those tests haven't ruled the harm out either. Relief alone doesn't settle your safety.
TB-500 and BPC-157 differ in their protein makeup
TB-500 and BPC-157 aren't chemically related. TB-500 matches part of thymosin beta-4. BPC-157 is a 15-amino-acid chain, with small protein parts joined together.
The Sports Medicine review from 2026 found encouraging animal results [15].
Both substances lack drug approval and strong human safety evidence. You don't have proof either will mend your injury.
TB-500's safety over years remains unknown
You don't have long-term human safety studies of TB-500. The larger protein, thymosin beta-4, had an early safety test, called Phase 1, lasting 14 days [6]. The study reported no serious harmful effects.
You don't get years of safety evidence from that short test.
Your possible tumor risk also remains unsettled [5]. Testing a different substance briefly can't settle your long-term safety.